Medicine recalls
|
| |
| Australia: APO-Cabergoline 500 mcg tablets: Recall - potential for degradation due to moisture |
| |
The Therapeutic Goods Administration (TGA) advised consumers and health professionals that Apotex, in consultation with the TGA, is recalling one batch of APO-Cabergoline 500 mcg tablets (batch no.: MK0903) due to a packaging issue which could potentially lead to the product degrading over time in moist conditions.
APO-Cabergoline is a medicine used to prevent the production of breast milk in women after giving birth, or to treat abnormally high levels of prolactin.
Consumers are advised to check the batch number displayed on the bottle label or the base of the carton, and return the affected product to the pharmacy where it was purchased for a refund or a replacement product.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/alert/apo-cabergoline-500-mcg-tablets
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/ Friday, September 02, 2016
Issued at HKT 13:00
|
| |
